Skip to content

Low dose versus moderate dose Prednisolone in Acute CPPD

Low dose VS Moderate dose of Prednisolone in treatment Acute CPPD : The Randomized Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20211224003
Enrollment
74
Registered
2021-12-24
Start date
2021-11-23
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute CPPD attack CPPD attack

Interventions

Oral prednisolone 5 mg twice daily,Oral prednisolone 15 mg twice daily
Experimental Drug,Active Comparator Drug
Prednisolone 10 mg/day,Prednisolone 30 mg/day

Sponsors

FACULTY OF MEDICINE VAJIRA HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients presented with an acute CPPD attack, and crystal-proven CPP crystal by arthrocentesis

Exclusion criteria

Exclusion criteria: 1. Secondary cause of CPPD - hemochromatosis - hyperparathyroidism - hypophosphatasia - hypomagnesemia 2. Septic arthritis or Uncontrolled systemic infection 3. DKA or HHS 4. BP >180/110 mmHg 5. Active GI hemorrhage 6. Prior use of colchicine or NSAIDs in past 1 week 7. Neurologic deficit causing decreased pain sensation around the involved joint 8. Intubated 9. Used of corticosteroid due to other indication (such as COPD with acute exacerbation)

Design outcomes

Primary

MeasureTime frame
time to complete resolution 28 days VAS score less than 2, swelling in the index joint (4-point Likert scale; 0), tender in the index joint (4-point Likert scale less than 1)

Secondary

MeasureTime frame
Time to clinical resolution 28 days VAS score,Recurrence rate of acute CPPD attack within 28 days 28 days new inflammation in any other joints

Countries

Thailand

Contacts

Public ContactWuttirak leelasattakul

NMU

wuttirak@nmu.ac.th0831706418

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026